IMPORTANT SAFETY INFORMATION
SUPRAX should only be used to treat infections that are proven or strongly suspected to be caused by bacteria.
Active* against uncomplicated urinary tract infection (UTI)
Minimum Inhibitory Concentrations (MIC) of SUPRAX®1
* In vitro susceptibility does not imply in vivo efficacy.
Delivers clinical successa
a Clinical success was defined as alleviation of fever without a recurrence during treatment and a negative urine culture after 72 hours of treatment
Susceptibility of isolates from children with UTIs (N=76)3a
1. Knapp CC, Sierra-Madero J, Washington JA. Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone. Antimicrob Agent Chemother. 1988;32(12):1896-1898. 2. Ludwig E. Cefixime in the treatment of respiratory and urinary tract infections. Chemotherapy. 1998;44(suppl 1):31-34. 3. Dagan R, Einhorn M, Lang R, et al. Once daily cefixime compared to twice-daily trimethoprim/sulfamethoxazole for treatment of urinary tract infections in infants and children. Pediatr Infect Dis J. 1992;11(3):198-203.
WARNINGS AND PRECAUTIONS
USE IN SPECIAL POPULATIONS
Please note this information is not comprehensive. Please visit www.supraxrx.com for full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088, or contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561.